Compare Dr. Reddys with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GLENMARK PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GLENMARK PHARMA DR. REDDYS LAB/
GLENMARK PHARMA
 
P/E (TTM) x 21.6 12.1 177.7% View Chart
P/BV x 3.2 1.7 186.0% View Chart
Dividend Yield % 0.7 0.6 131.2%  

Financials

 DR. REDDYS LAB   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
GLENMARK PHARMA
Mar-19
DR. REDDYS LAB/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875712 404.0%   
Low Rs1,888484 390.4%   
Sales per share (Unadj.) Rs930.2349.6 266.1%  
Earnings per share (Unadj.) Rs117.432.8 358.2%  
Cash flow per share (Unadj.) Rs185.844.3 419.0%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.80.3 250.9%  
Book value per share (Unadj.) Rs844.4198.6 425.1%  
Shares outstanding (eoy) m166.07282.17 58.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.61.7 149.8%   
Avg P/E ratio x20.318.2 111.3%  
P/CF ratio (eoy) x12.813.5 95.1%  
Price / Book Value ratio x2.83.0 93.7%  
Dividend payout %17.06.1 279.2%   
Avg Mkt Cap Rs m395,496168,625 234.5%   
No. of employees `00022.012.0 182.5%   
Total wages/salary Rs m33,56220,561 163.2%   
Avg. sales/employee Rs Th7,032.88,196.0 85.8%   
Avg. wages/employee Rs Th1,527.91,708.1 89.4%   
Avg. net profit/employee Rs Th887.7768.5 115.5%   
INCOME DATA
Net Sales Rs m154,48298,655 156.6%  
Other income Rs m3,3752,081 162.2%   
Total revenues Rs m157,857100,736 156.7%   
Gross profit Rs m31,78215,858 200.4%  
Depreciation Rs m11,3483,259 348.2%   
Interest Rs m8893,346 26.6%   
Profit before tax Rs m22,92011,335 202.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m3,8583,756 102.7%   
Profit after tax Rs m19,5009,250 210.8%  
Gross profit margin %20.616.1 128.0%  
Effective tax rate %16.833.1 50.8%   
Net profit margin %12.69.4 134.6%  
BALANCE SHEET DATA
Current assets Rs m111,10166,968 165.9%   
Current liabilities Rs m58,97340,211 146.7%   
Net working cap to sales %33.727.1 124.4%  
Current ratio x1.91.7 113.1%  
Inventory Days Days7983 95.2%  
Debtors Days Days9481 116.0%  
Net fixed assets Rs m101,24533,322 303.8%   
Share capital Rs m830282 294.1%   
"Free" reserves Rs m139,40655,770 250.0%   
Net worth Rs m140,23656,052 250.2%   
Long term debt Rs m22,00035,738 61.6%   
Total assets Rs m224,656132,888 169.1%  
Interest coverage x26.84.4 610.4%   
Debt to equity ratio x0.20.6 24.6%  
Sales to assets ratio x0.70.7 92.6%   
Return on assets %9.19.5 95.7%  
Return on equity %13.916.5 84.3%  
Return on capital %14.917.8 83.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67362,998 140.8%   
Fx outflow Rs m19,10422,859 83.6%   
Net fx Rs m69,56940,140 173.3%   
CASH FLOW
From Operations Rs m28,70413,242 216.8%  
From Investments Rs m-7,727-6,990 110.5%  
From Financial Activity Rs m-21,326-7,387 288.7%  
Net Cashflow Rs m-314-2,971 10.6%  

Share Holding

Indian Promoters % 25.5 48.3 52.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 6.9 78.3%  
FIIs % 35.3 34.4 102.6%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 56,727 133.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 19, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS